Autobio Diagnostics Co., Ltd.
603658
Kedudukan dalam Saham
#4904
Autobio Diagnostics Co., Ltd. specializes in the full lifecycle of clinical... Autobio Diagnostics Co., Ltd. specializes in the full lifecycle of clinical diagnostic products, from their initial research and development to manufacturing and market distribution. Their diverse offerings encompass a range of reagents for immunoassay, biochemistry, microbiology, and in-vitro diagnostics (IVD). Additionally, they provide advanced automated and semi-automated instrumentation, alongside comprehensive medical laboratory solutions. Notable immunoassay products include the AutoLumo A2000 Plus automatic chemiluminescence immunoassay analyzer, automated microplate chemiluminescent enzyme immunoassays, LUmo luminometers, PHOmo microplate readers, and iWO microplate washers. Within their microbiology division, they offer automated blood culture systems, blood culture bottles, AUTOMIC strips, and mycoplasma IES. Founded in 1998, the company originally operated as Lifeclone Diagnostics Co., Ltd. before adopting its current name, Autobio Diagnostics Co., Ltd., in 2003. Headquartered in Zhengzhou, China, it functions as a subsidiary of Zhengzhou Auto Industrial Co., Ltd.
Harga Saham
$5.15
Disegerakkan terakhir: 2026-10-22
Modal Pasaran
$2.94B
Perubahan (1 hari)
0.97%
Perubahan (1 tahun)
-5.80%
Negara
CN
Perdagangan Autobio Diagnostics Co., Ltd. (603658)
Kategori
Healthcare
Hasil untuk Autobio Diagnostics Co., Ltd. (603658)
Hasil pada Jun 2026 TTM: $632.52M
Menurut laporan kewangan terkini daripada Autobio Diagnostics Co., Ltd., hasil semasa syarikat (TTM) ialah $632.52M. Pada tahun 2024, syarikat memperoleh hasil sebanyak $612.57M penurunan berbanding hasil pada tahun 2023 iaitu $627.76M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Autobio Diagnostics Co., Ltd. dari 2011 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $632.52M | 4.71% |
| 2025 | $604.08M | -1.39% |
| 2024 | $612.57M | -2.42% |
| 2023 | $627.76M | -2.51% |
| 2022 | $643.91M | 8.68% |
| 2021 | $592.51M | 29.97% |
| 2020 | $455.88M | 18.47% |
| 2019 | $384.79M | 37.17% |
| 2018 | $280.53M | 30.36% |
| 2017 | $215.20M | 52.43% |
| 2016 | $141.18M | 27.96% |
| 2015 | $110.33M | 21.32% |
| 2014 | $90.94M | 34.75% |
| 2013 | $67.49M | 32.28% |
| 2012 | $51.02M | 51.82% |
| 2011 | $33.60M | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $47.35B | 7,386.03% |
US
|
|
| $25.61B | 3,948.54% |
US
|
|
| $2.71B | 327.98% |
US
|
|
| $8.02B | 1,167.55% |
CN
|
|
| $7.37B | 1,065.49% |
US
|
